预防性ICD获益预测:MADIT-ICD获益评分
本研究基于MADIT系列试验4531例患者,用Fine和Gray回归分别建立室速/室颤与非心律失常死亡的预后模型,整合竞争风险形成MADIT-ICD获益评分并分三组。最高获益组3年预测室速/室颤风险20%对非心律失常死亡7%,最低获益组为11%对12%,模型经内部和外部验证稳定。
要点
- MADIT-ICD评分通过权衡室速/室颤风险与非心律失常死亡风险来个体化预测预防性ICD获益。
- 最高获益组3年预测室速/室颤风险20%,明显高于非心律失常死亡风险7%。
- 最低获益组3年预测室速/室颤风险11%,与非心律失常死亡风险12%相近。
核心结论
- MADIT-ICD获益评分通过个体化评估室速/室颤风险与非心律失常死亡风险的权衡,预测预防性ICD的获益可能性。
研究设计与样本
- 研究人群为MADIT系列试验全部4531例患者,采用最佳子集Fine和Gray回归分析建立竞争风险预后模型。
主要发现
- 识别出8个室速/室颤预测因素:男性、年龄<75岁、既往非持续性室速、心率>75次/分、收缩压<140 mmHg、射血分数≤25%、心肌梗死、房性心律失常。
- 识别出7个非心律失常死亡预测因素:年龄≥75岁、糖尿病、体重指数<23 kg/m2、射血分数≤25%、NYHA≥II级、ICD与心脏再同步治疗除颤器对比、房性心律失常。
- 最高获益组3年预测室速/室颤风险为20%,非心律失常死亡风险为7%(P<0.001)。
- 中间获益组3年预测室速/室颤风险为15%,非心律失常死亡风险为9%(P<0.01)。
- 最低获益组3年预测室速/室颤风险为11%,非心律失常死亡风险为12%(P=0.41)。
关键数值与推荐
- 室速/室颤预测因素包括男性、年龄<75岁、既往非持续性室速、心率>75次/分、收缩压<140 mmHg、射血分数≤25%、心肌梗死、房性心律失常。
- 非心律失常死亡预测因素包括年龄≥75岁、糖尿病、体重指数<23 kg/m2、射血分数≤25%、NYHA≥II级、ICD与心脏再同步治疗除颤器对比、房性心律失常。
- 两个评分整合后形成三个MADIT-ICD获益组:最高获益组、中间获益组、最低获益组。
- 基于两个竞争风险评分在研究人群中的分布开发了个体化ICD获益评分(https://is.gd/madit)。
- 内部和外部验证确认模型稳定性。
临床怎么用
- 临床可借助MADIT-ICD获益评分,在考虑预防性ICD植入时个体化权衡室速/室颤风险与非心律失常死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The benefit of prophylactic implantable cardioverter-defibrillator (ICD) is not uniform due to differences in the risk of life-threatening ventricular tachycardia (VT)/ventricular fibrillation (VF) and non-arrhythmic mortality. We aimed to develop an ICD benefit prediction score that integrates the competing risks. METHODS AND RESULTS: The study population comprised all 4531 patients enrolled in the MADIT trials. Best-subsets Fine and Gray regression analysis was used to develop prognostic models for VT (≥200 b.p.m.)/VF vs. non-arrhythmic mortality (defined as death without prior sustained VT/VF). Eight predictors of VT/VF (male, age < 75 years, prior non-sustained VT, heart rate > 75 b.p.m., systolic blood pressure < 140 mmHg, ejection fraction ≤ 25%, myocardial infarction, and atrialarrhythmia) and 7 predictors of non-arrhythmic mortality (age ≥ 75 years, diabetes mellitus, body mass index < 23 kg/m2, ejection fraction ≤ 25%, New York Heart Association ≥II, ICD vs. cardiac resynchronization therapy with defibrillator, and atrial arrhythmia) were identified. The two scores were combined to create three MADIT-ICD benefit groups. In the highest benefit group, the 3-year predicted risk of VT/VF was three-fold higher than the risk of non-arrhythmic mortality (20% vs. 7%, P < 0.001). In the intermediate benefit group, the difference in the corresponding predicted risks was attenuated (15% vs. 9%, P < 0.01). In the lowest benefit group, the 3-year predicted risk of VT/VF was similar to the risk of non-arrhythmic mortality (11% vs. 12%, P = 0.41). A personalized ICD benefit score was developed based on the distribution of the two competing risks scores in the study population (https://is.gd/madit). Internal and external validation confirmed model stability. CONCLUSIONS: We propose the novel MADIT-ICD benefit score that predicts the likelihood of prophylactic ICD benefit through personalized assessment of the risk of VT/VF weighed against the risk of non-arrhythmic mortality.
引用
- Younis A, Goldberger JJ, Kutyifa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J. 2021. PMID: 33417692. doi:10.1093/eurheartj/ehaa1057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。